What CLSA says on Sun Pharma, M&M; Credit Suisse on Bharat Forge

On Sun Pharma, CLSA said FY23 revenue guidance was in-line with expectations led by speciality ramp up. The normalisation of expenses and higher input costs impacted profitability, it said.